Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)

October 8, 2024 9:17 AM EDT

Stifel analyst Dae Gon ha reiterated a Buy rating and $74.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

The analyst commented: "At face, today's FDA update on diazoxide choline-controlled release (DCCR) for Prader-Willi syndrome (PWS) comes as a... More

Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

October 8, 2024 9:14 AM EDT

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $65.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

The analyst commented: "This morning, Soleno announced that the FDA does not see a need to hold an advisory committee meeting to discuss DCCR ahead... More

Soleno Therapeutics (SLNO) Announces Regulatory Update on DCCR Extended-Release Tablets to Treat Prader-Willi Syndrome

October 8, 2024 8:31 AM EDT

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA).

The FDA Review Division has determined that... More